Cholangiocarcinoma Non-resectable Clinical Trial
Official title:
Evaluation of Bile Duct Patency After Photodynamic Therapy in Unresectable Cholangiocarcinomaļ¼a Prospective Non-randomized Controlled Study
Comparison of the bile duct patency with photodynamic therapy (PDT) and regular Endoscopic Retrograde Cholangiopancreatography(ERCP) stents in unresectable cholangiocarcinoma.
Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelium, accounting for about 70% of the malignant tumors of the bile duct system. Patients have no obvious clinical symptoms in the early stage. After late diagnosis, the effective treatment is surgical resection and & or liver transplantation, and chemotherapy is only used as adjuvant or palliative treatment. Some types of cholangiocarcinomas, such as hilar cholangiocarcinomas, are difficult to achieve radical resection due to their anatomical location, early invasions and are prone to recurrence with a poor long-term efficacy after surgery. Therefore, the comprehensive treatment of cholangiocarcinoma by multiple means urgently needs to be explored. In recent years, photodynamic therapy (PDT), as a new local treatment method, has attracted increasing attention. This study investigates the bile duct patency and effectiveness of photodynamic therapy compare with ordinary ERCP treatment for cholangiocarcinoma including the median survival, overall survival, and other indicators of side effects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03043547 -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
|
Phase 2 | |
| Terminated |
NCT03267940 -
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
|
Phase 1 | |
| Active, not recruiting |
NCT06081829 -
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
|
Phase 2 | |
| Completed |
NCT03473574 -
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
|
Phase 2 | |
| Completed |
NCT03377179 -
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT06192797 -
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Terminated |
NCT02166190 -
RFA RCT for Pancreatic or Bile Duct Cancer
|
N/A | |
| Recruiting |
NCT03364530 -
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05978609 -
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
|
Phase 2 | |
| Recruiting |
NCT05655949 -
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
|
Phase 2 | |
| Recruiting |
NCT06194695 -
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
|
||
| Recruiting |
NCT06192784 -
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Available |
NCT03414489 -
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
|